IndraLab

Statements

Baricitinib inhibits TYK2. 6 / 11
4 1 | 6
reach
"With low nanomolar inhibitory constants, ruxolitinib and tofacitinib are pan-JAK family inhibitors while baricitinib blocks the activity of JAK1, JAK2, and TYK2 ( Table 9 )."
35878738
reach
"Baricitinib was proposed as a potential treatment in severe COVID-19, because in addition to inhibiting JAK1 and JAK2, baricitinib also inhibits tyrosin-kinase 2 (TYK2)."
36851722
reach
"Baricitinib blocks the effect of activation of JAK1, JAK3 and TYK2, thus blocking the activation of several proinflammatory proteins [16]."
39533416
reach
"Deucravacitinib was approximately 56- to 120-fold more potent than tofacitinib, upadacitinib, and baricitinib at inhibiting TYK2-dependent IL-12–induced IFN-γ production in human whole blood."
34471993
reach
"Notably, baricitinib, at a high dose, also inhibits Tyk2, which mediates IL-10, IL-12/23, IL-6, and IL-4/13 signaling."
29728611
reach
"With low nanomolar effectiveness, ruxolitinib and tofacitinib are pan-JAK family inhibitors while baricitinib blocks the activity of JAK1, JAK2, and TYK2 ( Table 7 )."
36754102